Dr Graham Kelly developed a theory that dietary isoflavones were metabolised within the body into novel chemicals that possessed important hormone-like functions, and as such made important contributions to human health. That theory provided the basis for Graham leaving academia and founding the company Norvet which listed on the ASX in 1994. That company subsequently changed its name to Novogen and listed in the US on NASDAQ (1998).
Dr Kelly was the chief executive, executive chair and executive director of Novogen from 1994-2006. He also was the executive chair of Marshall Edwards which listed on London's AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma. Dr Kelly resigned from his executive and board positions at Novogen and MEI in 2006.
